Demographic Drivers
The GLP-1 analogues market, valued at USD 56.62 billion in 2025 and projected to grow at a CAGR of 21.39% from 2026 to 2034, is supported by expanded regulatory approvals for chronic weight management and cardiovascular risk reduction. Demographics add to this momentum. The geriatric population is at higher risk of diabetes and related conditions, and the report cites the UN projection that the global population aged 65 and above will more than double from 761 million in 2021 to 1.6 billion by 2050, with those aged 80 and above growing even faster.
Disease prevalence is also rising. According to the International Diabetes Federation, 537 million individuals were affected by diabetes worldwide in 2021, with more than 75% of adult cases in low and middle-income countries. New cases are expected to reach 643 million by 2030 and 783 million by 2045. Consumption of highly processed foods and the rising prevalence of obesity add to demand.
Regional Insights
North America held the largest regional share, at 45.0% in 2025. The American Diabetes Association reports that diabetes prevalence in the US was 11.6% in 2021, affecting 38.4 million Americans. The US is also a hub for leading pharmaceutical companies such as Novo Nordisk, whose extensive distribution networks support growth.
Asia Pacific is expected to register the highest CAGR, at 23.2%, due to an increasing proportion of older adults. According to the Asian Development Bank, the population aged 60 and above in the region is projected to nearly double to 1.2 billion by 2050, about 25% of the regional total. In India, a growing middle class and rising disposable incomes allow more patients to afford advanced diabetes and obesity treatments.
Distribution Channels
Online pharmacies are expected to be the fastest-growing distribution channel, at a 23.5% CAGR. Because these medications are often prescribed for chronic conditions that need long-term management, online pharmacies support continuous access and adherence through home delivery, automatic refills and fewer frequent pharmacy visits. Growth of telemedicine, accelerated by the COVID-19 pandemic, has increased online consultations and prescriptions, and patients who receive prescriptions through telehealth platforms are more likely to fill them online. The other channels in the report are hospital pharmacies and retail pharmacies.
Applications and Weight Management
Real-world use cases include blood glucose control, medical treatment for obese patients, cardiovascular risk reduction in diabetic patients, appetite control in metabolic disorders and chronic disease management. Because these therapies increase satiety and help control food intake, they are essential in weight management and in other metabolic conditions resulting from excessive weight gain.
Browse In-depth Market Research Report:
https://www.polarismarketresearch.com/industry-analysis/glp-1-analogues-market
The Role of AI and Market Challenges
The report highlights several ways AI may help: discovering new analogues from clinical and biological data, supporting personalized medicine through prediction of patient response and dosing, making clinical trials more efficient and aiding disease management and pharmacovigilance.
Challenges include high costs and restrictive insurance coverage, along with competition from alternative drugs. The report also mentions high prices and product shortages, while expecting continued investment in R&D and production. Rising regulatory approvals, reimbursement rates and awareness of weight-loss drugs are expected to support wider use. In January 2024, Glenmark Pharmaceuticals launched a biosimilar of liraglutide in India as Lirafit after approval from the Drug Controller General of India.
Key Players in the Market
- AstraZeneca
- Bristol-Myers Squibb Company
- D&D Pharmatech
- Eccogen
- Eli Lilly and Company
- Glenmark Pharmaceuticals Ltd.
- Hanmi Pharm. Co., Ltd.
- Lexicon Pharmaceuticals, Inc.
- Merck & Co., Inc.
- Novo Nordisk A/S
- Sanofi
Conclusion
Demand in the GLP-1 analogues market is underpinned by aging populations, rising diabetes and obesity prevalence and expanding regulatory acceptance. North America remains the largest region, Asia Pacific offers the fastest growth, and digital channels are changing how patients obtain long-term therapy. Companies that manage affordability and supply, support adherence through convenient access and use data-driven tools to refine treatment and trials are best positioned in this fast-growing market.
More Trending Latest Reports By Polaris Market Research: